Urine screening by Seldi-Tof , followed by biomarker identification , in a Brazilian cohort of patients with Renal Cell Carcinoma

ARTICLE INFO _________________________________________________________ ___________________ Vol. 39 (2): 228-239, March April, 2013 doi: 10.1590/S1677-5538.IBJU.2013.02.12 IBJU | uRine scReening by seldi-tof in patients with Renal cell caRcinoMa 229 the process of apoptosis and the cleavage of membrane proteins that are secreted. High molecular weight proteins (albumin, for example) are able to pass through the glomerular filtrate. Small proteins, or peptides (< 10 kDa) are easily filtered by the glomerulus and constitute an important source of information, even if the peptide is the result of proteolysis of larger proteins circulating in plasma (1-3). Urine is especially attractive for biomarker discovery in urological diseases since any change in concentration of proteins in plasma will reflect in the urine. Mass Spectroscopy (MS) is an analytical technique that measures the mass-to-charge ratio of charged particles. It is used for determining the composition of a sample or molecule, and for elucidating the chemical structures of molecules, such as peptides and other chemical compounds. MS works by ionizing chemical compounds; the ions are then accelerated through a potential difference and focused into a beam. The ion beam passes through a magnetic field which bends the charged stream. Lighter components or components with more ionic charge will deflect in the field more than heavier or less charged components. The final element of a MS is the detector. The detector records either the charge induced or the current when an ion passes by or hits a surface. In a scanning instrument, the signals will generate a mass spectrum, a record of ions expressed as m/z (mass/charge). MS/MS is the tandem mass spectrometry consisting of two mass spectrometers in series connected by a chamber known as a collision cell. The sample to be examined is essentially sorted and weighed in the first mass spectrometer, then broken into pieces in the collision cell, and a piece or pieces sorted and weighed in the second mass spectrometer. Identification by MS/MS is considered more accurate. The technology of SELDI-TOF (Surface Enhanced Laser Desorption Ionization Time of Flight) is a kind of mass spectrometer (MS). The instrument enables the separation of proteins and peptides by their physical properties (hydrophobic, hydrophilic, acidic, basic, with affinity for metal etc.) on a solid surface called Chip. The time-of-flight (TOF) analyzer measures the time they take to reach the detector. Ions velocities will depend on their masses and lighter ions will reach the detector first. The SELDI-TOF is very sensitive instrument and is able to detect proteins in fluids like urine without previous processing. In spite of some new drugs for treatment (4), RCC is a disease that would benefit from improvement of early detection. More than 30% of patients show locally advanced or metastatic disease at diagnosis. Furthermore, approximately 40% of patients undergoing curative surgery for localized disease relapse. In search of possible biomarkers, we have screened proteins/peptides in individual samples of urine from 61 RCC Brazilian patients of the two most common histological subtypes (Clear Cell (CC) and Papillary). MATERIAL AND METHODS Patients and Controls Patients and control individuals included in this study were adults of both genders, smokers and nonsmokers. This study was approved by the Ethics Committee of Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil, registration # 38/05. Urine samples were obtained from 61 untreated adult patients attending to the Departments of Urology of Instituto Nacional de Câncer and Hospital Mário Kröeff. Histological classification followed WHO guidelines. Table-1 shows the histological data as well as patient gender, Fuhrman grade, stage, follow-up and outcome. We were unable to establish the Fuhrman grade in a patient with papillary RCC type I. Patient follow-up data were gathered from medical charts and when necessary through contact with the patient family. We retrospectively reviewed the charts to determine dates of recurrence and death, as well as cause of death. Mean and median patient age was 59 and 55 years at diagnosis (range 27 to 84), respectively. Follow-up was evaluated in 61 patients. Median follow-up was 38 months (range 1 to 75). Patients with genetic syndromes or mental illness or immunodeficiency or who have been treated for cancer before were excluded from this study. Other exclusion criteria were the presence of proteinuria, microalbuminuria (diabetes mellitus), auto immune IBJU | uRine scReening by seldi-tof in patients with Renal cell caRcinoMa 230 Ta bl e 1 P at ie nt d at a, h is to pa th ol og ic al fi nd in gs , t um or s ta ge a nd s ur vi va l a na ly si s. Pt s. Ge nd er Hi st ol og ic al T yp e Fu rh m an G ra de St ag e Fo llo w -u p (m on th s) De at hs b y Di se as e 1 Fe m al e cc RC C I T1 aN xM 0 55 2 Fe m al e cc RC C I T2 aN xM x 62 3 M al e cc RC C I T1 aN xM x 1 4 Fe m al e cc RC C I T1 aN xM 0 66 5 M al e cc RC C I T2 aN 0M 0 37 6 Fe m al e cc RC C II T1 bN xM 0 61 7 M al e cc RC C II T1 bN xM 0 67 8 M al e cc RC C II T3 aN xM x 66 9 Fe m al e cc RC C II T1 bN xM x 65 10 M al e cc RC C II T1 bN xM x 75 11 M al e cc RC C II T1 aN 0M 0 64 12 M al e cc RC C II T1 aN xM x 9 13 M al e cc RC C II T3 aN xM x 61 14 M al e cc RC C II T3 aN xM x 61 15 Fe m al e cc RC C II T1 bN xM x 60 16 Fe m al e cc RC C II T1 aN xM x 59 17 M al e cc RC C II T1 bN 0M x 47 18 Fe m al e cc RC C II T1 bN xM x 54 19 M al e cc RC C II T1 bN xM x 36 20 M al e cc RC C II T2 aN xM x 36 21 Fe m al e cc RC C II T3 bN 0M x 2 IBJU | uRine scReening by seldi-tof in patients with Renal cell caRcinoMa 231 22 Fe m al e cc RC C II T2 aN xM 0 29 23 M al e cc RC C II T1 bN xM x 32 24 Fe m al e cc RC C II T3 aN xM x 9 25 M al e cc RC C II T3 aN xM x 30 26 M al e cc RC C II T1 bN xM 0 27 27 Fe m al e cc RC C II T3 aN xM x 25 28 M al e cc RC C II T3 aN xM x 11 29 M al e cc RC C II T3 aN 2M x 40 30 Fe m al e cc RC C III T3 aN xM x 3 31 M al e cc RC C III T3 aN xM x 64 32 Fe m al e cc RC C III T1 N0 M 0 63 33 M al e cc RC C III T3 aN xM 0 56 34 M al e cc RC C III T3 aN xM x 1 35 M al e cc RC C III T3 aN xM x 15 36 Fe m al e cc RC C III T2 aN xM x 54 37 M al e cc RC C III T3 bN 0M x 22 38 M al e cc RC C III T3 aN xM x 58 39 M al e cc RC C III T3 aN 1M x 2 40 M al e cc RC C III T3 bN x M x 53 41 M al e cc RC C III T3 aN xM x 33 42 M al e cc RC C III T2 aN 0M 0 32 43 M al e cc RC C III T1 bN 1M 0 28 44 Fe m al e cc RC C III T2 aN 0M x 26 45 M al e cc RC C III T3 aN 0M 0 21 IBJU | uRine scReening by seldi-tof in patients with Renal cell caRcinoMa 232 46 Fe m al e cc RC C IV T2 bN xM x 64 47 M al e cc RC C IV T1 bN 0M 0 7 48 Fe m al e cc RC C IV T3 aN xM 0 30 49 Fe m al e cc RC C IV T2 bN xM x 6 50 M al e cc RC C IV T3 aN 2M x 22 51 Fe m al e cc RC C IV T2 bN 2M x 6 52 M al e cc RC C IV T2 N0 M 0 1 53 Fe m al e cc RC C IV T1 bN 0M 0 27 54 M al e Pa pi lla ry R CC ty pe I -T1 aN xM 0 5 55 Fe m al e Pa pi lla ry R CC ty pe I II T1 bN 0M 0 30 56 Fe m al e Pa pi lla ry R CC ty pe I II T2 aN xM 0 50 57 Fe m al e Pa pi lla ry R CC ty pe I II T1 Nx M 0 39 58 Fe m al e Pa pi lla ry R CC ty pe II II T3 aN 0M 0 48 59 M al e Pa pi lla ry R CC ty pe II II T2 bN 1M 0 55 60 M al e Pa pi lla ry R CC ty pe II III T2 bN xM x 14 61 Fe m al e Pa pi lla ry R CC ty pe II IV T2 bN xM 0 32 IBJU | uRine scReening by seldi-tof in patients with Renal cell caRcinoMa 233 glomerulopathies, chronic kidney disease, urinary tract infections, lithiasis and prostatic diseases. Twenty-nine control urine samples were obtained from over 40 years old healthy individuals from Laboratory of Molecular Biology, Department of Urology, Jena University Hospital, Germany. Control individuals had no indications of kidney abnormalities. Urine Collection The 10-20 mL first-void urine was discarded; the following 50-70 mL urine was collected, centrifuged at 1,000g for 10 minutes and the supernatant saved (5). Phenylmethanesulfonyl fluoride (PMSF) was added to the urine samples at final concentration of 1mM, aliquoted and frozen at -70oC. Binding conditions of urine proteins to the chips Aliquots of urine were thawed in ice and were then vortexed at full power (6). Thereafter, all procedures were carried out at room temperature. All experiments were performed in duplicate. Three kinds of chips, IMAC30, Q-10 and CM10 (BIORAD), were tested. The operating mechanism of the ProteinChip IMAC30 is the reversible binding of proteins to the surface through a coordinated metal interaction. The ProteinChip IMAC30 array incorporates nitrilotriacetic acid (NTA) groups and is capable of forming stable octahedral complexes with polyvalent metal ions, including Cu2+,Ni2+, Fe3+, and Ga3+. After loading the array surface with the desired metal ion, two free sites are available from the formed octahedral complex for interaction with specific amino acid residues (such as His) or posttranslational modifications such as phosphate groups. To generate selectivity, binding and washing buffers may contain increasing concentrations of competitors, such as imidazole, which compete with the coordinated metal on the NTA group for binding to the protein or peptide. Q10 incorporates quaternized ammonium groups (positively charged) and thus acts as a strong anion exchanger. The Q10 surface binds peptides and proteins that are negatively charged at a given pH. By maintaining the pH of the binding or washing buffer at alkaline conditions (e.g., pH 8), an overall net negative charge is imparted on a greater number of proteins within the sample (therefore more binding). By decreasing the pH of the binding or washing buffer, an overall net positive charge is imparted on the proteins, resulting in less binding (i.e., more specificity). CM10 incorporates a carboxylate chemistry (negatively charged) and thus acts as a weak cationic exchanger. CM10 surface binds proteins that are positively charged


INTRODUCTION
Urine analysis is a non-invasive method of clinical analysis and has been used primarily to monitor diseases of the urogenital tract.In a pe-riod of 24 hours, normal urine shows 150 milligrams of proteins and peptides that are derived from a variety of sources.Most of them come from the glomerular filtrate of plasma, while others from Urine screening by Seldi-Tof, followed by biomarker identification, in a Brazilian cohort of patients with Renal Cell Carcinoma (RCC) _______________________________________________ the process of apoptosis and the cleavage of membrane proteins that are secreted.High molecular weight proteins (albumin, for example) are able to pass through the glomerular filtrate.Small proteins, or peptides (< 10 kDa) are easily filtered by the glomerulus and constitute an important source of information, even if the peptide is the result of proteolysis of larger proteins circulating in plasma (1)(2)(3).Urine is especially attractive for biomarker discovery in urological diseases since any change in concentration of proteins in plasma will reflect in the urine.
Mass Spectroscopy (MS) is an analytical technique that measures the mass-to-charge ratio of charged particles.It is used for determining the composition of a sample or molecule, and for elucidating the chemical structures of molecules, such as peptides and other chemical compounds.MS works by ionizing chemical compounds; the ions are then accelerated through a potential difference and focused into a beam.The ion beam passes through a magnetic field which bends the charged stream.Lighter components or components with more ionic charge will deflect in the field more than heavier or less charged components.The final element of a MS is the detector.The detector records either the charge induced or the current when an ion passes by or hits a surface.In a scanning instrument, the signals will generate a mass spectrum, a record of ions expressed as m/z (mass/charge).
MS/MS is the tandem mass spectrometry consisting of two mass spectrometers in series connected by a chamber known as a collision cell.The sample to be examined is essentially sorted and weighed in the first mass spectrometer, then broken into pieces in the collision cell, and a piece or pieces sorted and weighed in the second mass spectrometer.Identification by MS/MS is considered more accurate.
The technology of SELDI-TOF (Surface Enhanced Laser Desorption Ionization -Time of Flight) is a kind of mass spectrometer (MS).The instrument enables the separation of proteins and peptides by their physical properties (hydrophobic, hydrophilic, acidic, basic, with affinity for metal etc.) on a solid surface called Chip.The time-of-flight (TOF) analyzer measures the time they take to reach the detector.Ions velocities will depend on their masses and lighter ions will reach the detector first.The SELDI-TOF is very sensitive instrument and is able to detect proteins in fluids like urine without previous processing.
In spite of some new drugs for treatment (4), RCC is a disease that would benefit from improvement of early detection.More than 30% of patients show locally advanced or metastatic disease at diagnosis.Furthermore, approximately 40% of patients undergoing curative surgery for localized disease relapse.In search of possible biomarkers, we have screened proteins/peptides in individual samples of urine from 61 RCC Brazilian patients of the two most common histological subtypes (Clear Cell (CC) and Papillary).

Patients and Controls
Patients and control individuals included in this study were adults of both genders, smokers and nonsmokers.This study was approved by the Ethics Committee of Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil, registration # 38/05.Urine samples were obtained from 61 untreated adult patients attending to the Departments of Urology of Instituto Nacional de Câncer and Hospital Mário Kröeff.Histological classification followed WHO guidelines.Table-1 shows the histological data as well as patient gender, Fuhrman grade, stage, follow-up and outcome.We were unable to establish the Fuhrman grade in a patient with papillary RCC type I. Patient follow-up data were gathered from medical charts and when necessary through contact with the patient family.We retrospectively reviewed the charts to determine dates of recurrence and death, as well as cause of death.Mean and median patient age was 59 and 55 years at diagnosis (range 27 to 84), respectively.Follow-up was evaluated in 61 patients.Median follow-up was 38 months (range 1 to 75).Patients with genetic syndromes or mental illness or immunodeficiency or who have been treated for cancer before were excluded from this study.Other exclusion criteria were the presence of proteinuria, microalbuminuria (diabetes mellitus), auto immune  glomerulopathies, chronic kidney disease, urinary tract infections, lithiasis and prostatic diseases.
Twenty-nine control urine samples were obtained from over 40 years old healthy individuals from Laboratory of Molecular Biology, Department of Urology, Jena University Hospital, Germany.Control individuals had no indications of kidney abnormalities.

Urine Collection
The 10-20 mL first-void urine was discarded; the following 50-70 mL urine was collected, centrifuged at 1,000g for 10 minutes and the supernatant saved (5).Phenylmethanesulfonyl fluoride (PMSF) was added to the urine samples at final concentration of 1mM, aliquoted and frozen at -70 o C.

Binding conditions of urine proteins to the chips
Aliquots of urine were thawed in ice and were then vortexed at full power (6).Thereafter, all procedures were carried out at room temperature.All experiments were performed in duplicate.Three kinds of chips, IMAC30, Q-10 and CM10 (BIORAD), were tested.
The operating mechanism of the Protein-Chip IMAC30 is the reversible binding of proteins to the surface through a coordinated metal interaction.The ProteinChip IMAC30 array incorporates nitrilotriacetic acid (NTA) groups and is capable of forming stable octahedral complexes with polyvalent metal ions, including Cu2+,Ni2+, Fe3+, and Ga3+.After loading the array surface with the desired metal ion, two free sites are available from the formed octahedral complex for interaction with specific amino acid residues (such as His) or posttranslational modifications such as phosphate groups.To generate selectivity, binding and washing buffers may contain increasing concentrations of competitors, such as imidazole, which compete with the coordinated metal on the NTA group for binding to the protein or peptide.
Q10 incorporates quaternized ammonium groups (positively charged) and thus acts as a strong anion exchanger.The Q10 surface binds peptides and proteins that are negatively charged at a given pH.By maintaining the pH of the binding or washing buffer at alkaline conditions (e.g., pH 8), an overall net negative charge is imparted on a greater number of proteins within the sample (therefore more binding).By decreasing the pH of the binding or washing buffer, an overall net positive charge is imparted on the proteins, resulting in less binding (i.e., more specificity).
CM10 incorporates a carboxylate chemistry (negatively charged) and thus acts as a weak cationic exchanger.CM10 surface binds proteins that are positively charged at a given pH.To generate selectivity, the pH of the binding buffer is increased or decreased, depending on the need.By decreasing the pH of the binding and washing buffers, an overall net positive charge is imparted on a greater number of proteins within the sample (therefore more binding).By increasing the pH of the binding and washing buffers, an overall net negative charge is imparted on the proteins, resulting in less binding (i.e., more specificity).
Alternatively, 50µL of pure urine were loaded with appropriate buffers in a bioprocessor (Ciphergen) for 90 minutes on a shaker.The chips were then washed, on a shaker, three times with the same buffers and two times with deionized water and air dried.A saturated solution of sinapinic acid (SPA) was prepared and 2x 0.5µL was applied in each spot.

Spectral data processing and statistical analysis
Pure urines from 29 cases of low grade ccRCC (Fuhrnann grade I + II), 24 from high grade ccRCC (Fuhrnann grade III + IV), 8 from were Papillary RCC (Fuhrnann grade II + III + IV) and 29 controls were individually analyzed in a Pro-teinChip Reader PCS 4,000 (Ciphergen Biosyste- Urine pool fractionation with RP beads followed by SDS page gel RP resins are a family of polymeric media useful for sample fractionation.RP beads are porous spherical beads, containing a surface area that is chemically stable to maximize extraction efficiency.The beads resin shows special characte-ristics such as: non-polar, non-ionic, ultra-clean, highly crossed-linked polymers that differ in particle size, pore size and surface area.The pore size large is selected according elements to enter into the pore and to adsorb onto the pore surface.Among the applications are exchange solvents, separate hydrophobic molecules by size and desalt samples. Twenty mL of pooled urine from the control group were used for this experiment and mixed with 200μL of equilibrated RP beads (Polymer Laboratories Ltd., 15-20μm, 300Å, cat.1412-2201) that were equilibrated in 10% acetonitrile/0.1% trichloroacetic acid.After 30 minutes incubation with mixing, the sample was centrifuged at 1,500g for 8 minutes and the supernatant was discarded.
The sample was fractionated into six fractions by sequential elution with 100μL aliquots of elution buffer with increasing concentrations of acetonitrile in 0.1% trichloroacetic acid (10-100% acetonitrile).Two μL of each fraction was directly spotted on the CM10 and analyzed by SELDI-TOF for selection.The fraction containing the protein of interest was concentrated in a vacuum centrifuge and loaded on a precast 12% SDS-PAGE gel (Invitrogen).Protein fractions co-migrated with the molecular maker Page Ruler Plus (Fermentas, cat.SM 1811).The gel was stained with Simply Blue Safe Stain (Enhanced Coomassie, Invitrogen).

Gel band trypsinization
The band of interest was excised from the stained gel and destained overnight with a mix of methanol 50% and acetic acid 10%.The gel piece was dehydrated in 100% acetonitrile for 30 minutes, dried in a vacuum centrifuge.Ten ng/mL of sequencing grade trypsin (Promega, UK) in 50 mM ammonium bicarbonate was added to dried gel piece and incubated at 37oC overnight.

MS/MS Analysis
The resulting peptides were analyzed in a MALDI TOF/TOF with a Bruker ultraflex device (Bruker Daltonics, Bremen, Germany).Briefly, samples were prepared in dried-droplet-preparation with α-hydroxy-cyano-cinnamic acid (CHCA).Peptide mass fingerprint and peptide fragmentation spectra of each sample were sub-mitted for identification using MASCOT interface (MASCOT inhouse server 2.1.03,Matrix Science, London, UK) for search in the NCBI database.Hits were considered significant according to the MASCOT score (P = 0.05).

Binding conditions to the chips
Tests were performed with 3 different chips (IMAC30, Q-10 and CM10, BIORAD).The quantity of peaks that were produced in each condition was considered.The protocol applying fractions produced by the Protein Chip Serum Fraction kit did not improve the number of peaks and their intensity, no matter the chip.The protocol of pre--denaturing of the urine has not improved the results as well.The highest number of peaks were generated when pure urine samples were applied on CM10 chip therefore it was selected to perform the screening of RCC urines.

Peaks selection and identification
For analysis, the urine samples were clustered according to the histological classification and compared to 29 control samples.We observed 22 peaks (m/z) that were statistically overexpressed (p < 0.05) in the control group.The most significant peaks are listed at Table-2.An example of differently expressed peak is shown in Figure -2.
The selected RP fractions of the control urine pool were loaded in a SDS PAGE gel (Figure -3)   and bands of most interest (A and B) were excised for identification.Table 3 shows the results of the MS/MS analysis of bands A and B (Figure -3).

COMMENTS
The under detection of peaks in the urines of ccRCC and in Papillary RCC patients by SELDI--TOF screening was remarkable.This could be understandable by protein degradation in urine of these patients.The loss of proteins was noticed before by Sherief et al. (7) who reported that urinary extracellular matrix proteins laminin, collagen IV and fibronectin, which are known to be secreted by renal epithelial cells, were significantly decreased or absent in the urine specimens of patients with RCC.Corroborating to this, the metalloproteinase (MMP) activity was found higher in the urine of RCC patients (7).The elevated levels of MMP activity shall result in extracellular matrix proteins degradation that were either decreased or absent in the patients urines.Therefore, the explanation for the under detection of peaks reported herein could be due to protein degradation in the same way.Nevertheless, we cannot completely rule out that the results contain any bias due to the methods that were applied.
Proteins that were identified from urine of controls by MS/MS analysis were immunoglobulin light chain, albumin, secreted and transmembrane 1 precursor (protein K12), mannan-binding lectin-associated serine protease-2 (MASP-2) and vitelline membrane outer layer 1 isoform 1 (Table-3).Identification of immunoglobulins and isoforms of albumin are quite common by proteomics and therefore cannot be considered as possible molecular markers.On the other hand, the other 3 identified proteins should be taken into consideration.The peptides sequences (Table -3) from each one of these proteins were checked on uniprot data bank (www.uniprot.org)and they all corresponded 100% to the proteins assigned.
Expression of mRNA of K12 gene (SECTM1) was detected at the highest levels in peripheral blood leukocytes and breast cancer cell lines.Western blots showed that the K12 protein exists as a cluster of bands around 27 kDa, and extractions using nonionic detergents or high pH conditions demonstrate that it behaves as an integral membrane protein.Immunofluorescence localization studies reveal that K12 is not detectable on the cell surface, but instead is found in a perinuclear Golgi-like pattern and colocalizes with a well-known Golgi marker.In addition, an approximately 20-kDa soluble form of the K12 protein derived from the N-terminal domain is specifically secreted by cells into the culture medium.Immunohistochemical analysis of peripheral blood cells shows that K12 is found in leukocytes of the myeloid lineage, with the strongest staining observed in granulocytes and no detectable expression in lymphocytes.Based on its range of expression, it is possible that K12 is a protein with potential importance in hematopoietic and/ or immune system processes (8).Mannan-binding lectin (MBL) is an oligomeric serum lectin that plays a role in innate immunity by activating the complement system.In human, two types of MBL-associated serine protease (MASP-1 and MASP-2) and a truncated protein of MASP-2 (small MBL-associated protein; sMAP or MAp19) are complexed with MBL (9).After activation by auto-catalytic cleavage, MASP-2 cleaves C2 and C4, leading to their activation and to the formation of C3 convertase.
Vitelline membrane outer layer 1 isoform 1 belongs to the family VMO1 that is conserved in the chicken, in the mouse and in human.In chickens, this protein participates in the construction of the vitelline membrane portion of the egg shell, a rigid structure required to maintain the shape of the egg (10).The role of this protein in humans is unknown, actually it was never purified.It was inferred from electronic annotation and probably is secreted.
Amazingly, the down expression of protein K-12 and MASP-2 were observed in two histological subtypes (ccRCC and Papillary) which show differentiated origin in the kidney and distinguished genetics alterations.Papillary RCCs are characterized by trisomy of chromosomes 3q, 7, 8, 12, 16, 17, and 20 and loss of the Y.On the other hand, chromosome 3p deletion is the most typical genetic alteration in ccRCC, present in 75.8% of cases which coincides with von Hippel-Lindau disease (11).This fact creates the possibility that a subtype independent RCC urine marker could be in the way.K-12 and MASP-2 should be tested in the urine of other RCC histological subtypes, although they are much less frequent than ccRCC and Papillary.

CONCLUSIONS
The down expression of Protein K-12 and MASP-2 make them good candidates for RCC urine makers and should be validated in a bigger cohort including the other less common histological RCC subtypes.Probably, these proteins were found in the control urine as a consequence of blood filtration role developed by the kidney.The lower abundance of these proteins in the patients' urine could be a consequence of their degradation or of kidney failure.
Figure-1a shows the assembling of chips into a frame that will go into a bioprocessor (Figure-1b); Figure-1c shows a chip being inserted into the SELDI-TOF).

Figure 1 A
Figure 1 A-C -Assembling of chips into the bioprocessor and insertion of a chip into the SELDI-TOF.

Figure 2 -
Figure 2 -Spectra showing the peak of approximately 23,600 that is underexpressed in patients.

Figure 3 -
Figure 3 -Isolation of bands of interest from a Coomassie Blue stained 12% SDS PAGE gel from fraction eluted with 60% acetonitrile.Arrows indicate the bands of interest of approximately 9,770 (A) and 23,600 (B).

Table 3 -Protein identified by MS/MS.
1 NCBI: National Center for Biotechnology Information: numbering refers to the protein in database 2 Score: ideal value is above 353Theoretical molecular weight;4Representative peptides: trypic peptides in which the analyses were based.